TuHURA Biosciences (HURA) has appointed Craig Tendler, M.D. to its Board of Directors effective March 10, 2025. During his tenure at Johnson & Johnson (JNJ), Dr. Tendler and his team worked in collaboration with the FDA and the European Medicines Agency to secure the worldwide approvals of transformational treatments in prostate cancer, hematologic malignancies as well as for lung and bladder cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA: